Eversheds Sutherland Advises on Irrimax Acquisition by ARCHIMED
September 09, 2024
Eversheds Sutherland Advises on Irrimax Acquisition by ARCHIMEDSeptember 09, 2024 Eversheds Sutherland is pleased to announce that it advised Irrimax Corporation (including its holding company, Innovation Technologies) on its acquisition by global private equity healthcare specialist ARCHIMED for an undisclosed sum. Lawrenceville, Georgia-based Irrimax, founded in 2003, develops and markets Irrisept® Antimicrobial Wound Lavage, a market-leading solution within high performance wound irrigation. The partnership between the two firms will help Irrimax expand its product range, markets and global reach. ARCHIMED acquired Irrimax through its MED Platform II fund, which closed at €3.5 billion in June 2023, a record at the time for a buyout fund exclusively investing in healthcare industries, according to data from Preqin. The MED Platform funds partner with category leaders in the mid-cap global healthcare market. The funds provide platform companies with the strategic, tactical, and financial resources they need to accelerate innovation, grow capacity, broaden product lines, and expand into new regions, organically and through acquisitions. The ARCHIMED press release is available here. Eversheds Sutherland Corporate Partner Wade Stribling led the deal, with support from Corporate Partner Chris Rosselli, Tax Partner Laura Taylor and Corporate Associates Grant Cole, Jazmen Howard and Haley Klass. Key contacts
Wade H. Stribling Partner Atlanta, United States Christopher M. Rosselli Partner Atlanta, United States Laura Taylor Partner Washington, DC, United States Grant D. Cole Associate Atlanta, United States Jazmen B. Howard Senior Associate Atlanta, United States Haley E. Klass Associate Atlanta, United States Latest Insights
Latest Events |